Could ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding?

Basit Öğe Kaydı
dc.contributor.authorKIRAN, TUGBA RAIKA
dc.contributor.authorDoğan, Ümran Karabulut
dc.contributor.authorOtlu, Önder
dc.contributor.authoryildirim, engin
dc.contributor.authorErdem, Mehmet
dc.contributor.authorİnceoğlu, Feyza
dc.date.accessioned2025-10-24T18:03:58Z
dc.date.available2025-10-24T18:03:58Z
dc.date.issued2024
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAim: Abnormal uterine bleeding (AUB) is a health problem characterized by various symptoms such as heavy and prolonged menstrual bleeding, affecting approximately 30% of female patients both physiologically and psychologically. The objective of this study was to assess serum Elabela (ELA) concentrations in women aged 18 and above diagnosed with functional AUB, and to compare these concentrations with those of healthy women. Material and Method: This prospective case-control study was performed from August 18, 2022 to December 30, 2022. This was a cross-sectional study including 50 women who applied to the gynecology service of Malatya Turgut Özal Training and Research Hospital with complaints of AUB and 50 women without AUB who underwent gynecological examination. The presence of AUB in patients was determined based on clinical examination conducted by a gynecologist and medical records. Demographic and clinical characteristics were recorded. Serum ELA levels were determined by commercial ELISA kit. Results: Serum ELA levels was significantly lower in patients with AUB (581.54±272.25 pg/mL) compared to the healthy group (744.55±300.31 pg/mL, p=0.005). In this study, ELA in patients with AUB showed 98% sensitivity and 80% specificity with a cut off value of 411.41 pg/mL (area under the curve [AUC], 68.1%; p=0.002). Conclusion: Serum ELA levels in patients with AUB were significantly lower than in healthy women. These results show that ELA is a good predictor of the pathophysiological process of AUB.
dc.identifier.doi10.37990/medr.1490041
dc.identifier.endpage418
dc.identifier.issn2687-4555
dc.identifier.issue3
dc.identifier.startpage413
dc.identifier.trdizinid1270657
dc.identifier.urihttps://doi.org/10.37990/medr.1490041
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1270657
dc.identifier.urihttps://hdl.handle.net/20.500.12899/2573
dc.identifier.volume6
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofMedical records-international medical journal (Online)
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzTR-Dizin_20251023
dc.subjectElabela
dc.subjectPALM-COEIN
dc.subjectabnormal uterine bleeding
dc.titleCould ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding?
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu